Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aligos Therapeutics (NAS:ALGS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Aligos Therapeutics Days Sales Outstanding Related Terms
Aligos Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALGS vs CRVO, PVCT, PSTV: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Aligos Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Days Sales Outstanding falls into.
Aligos Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a Days Sales Outstanding of 91.25 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #762 out of 838 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Aligos Therapeutics' Days Sales Outstanding too high?
Aligos Therapeutics' current Days Sales Outstanding is 91.25. The Biotechnology industry median Days Sales Outstanding is 69.00. Aligos Therapeutics' value of 91.25 is 32.2% above this industry median. Based on the distribution chart, Aligos Therapeutics ranks #762 out of 838 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Days Sales Outstanding compare to CRVO and PVCT?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #762 out of 838 companies for Days Sales Outstanding. This places Aligos Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 69.00. Aligos Therapeutics' value of 91.25 is 32.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.00, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current Days Sales Outstanding of 91.25 is 32.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current Days Sales Outstanding is 91.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $33.37, compared to a current price of $6.84 — trading 79.5% below its estimated fair value. The current Days Sales Outstanding is 91.25 and 32.2% above the Biotechnology industry median of 69.00. Aligos Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Days Sales Outstanding is 91.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued.
The current stock price of $6.84 is trading 79.5% below its estimated GF Value™ of $33.37.
GuruFocus considers Aligos Therapeutics to be Possible Value Trap.
Key valuation signals for ALGS:
Days Sales Outstanding: 91.25
GF Value™: $33.37 vs. price of $6.84 (79.5% below fair value)
Industry Position: 32.2% above the Biotechnology median (#762 of 838)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score
Get the complete analysis for ALGS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
